Cargando…

Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Treatment

(1) Background: We aimed to evaluate the risk of hepatitis B virus (HBV) reactivation in lung cancer patients treated with tyrosine kinase inhibitor (TKI), particularly in those with resolved HBV infection. (2) Methods: In this retrospective hospital-based cohort study, we screened all lung cancer p...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Po-Hsin, Huang, Yen-Hsiang, Hsu, Yu-Wei, Chen, Kun-Chieh, Hsu, Kuo-Hsuan, Lin, Ho, Lee, Teng-Yu, Tseng, Jeng-Sen, Chang, Gee-Chen, Yang, Tsung-Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820864/
https://www.ncbi.nlm.nih.gov/pubmed/36615034
http://dx.doi.org/10.3390/jcm12010231
_version_ 1784865562010058752
author Lee, Po-Hsin
Huang, Yen-Hsiang
Hsu, Yu-Wei
Chen, Kun-Chieh
Hsu, Kuo-Hsuan
Lin, Ho
Lee, Teng-Yu
Tseng, Jeng-Sen
Chang, Gee-Chen
Yang, Tsung-Ying
author_facet Lee, Po-Hsin
Huang, Yen-Hsiang
Hsu, Yu-Wei
Chen, Kun-Chieh
Hsu, Kuo-Hsuan
Lin, Ho
Lee, Teng-Yu
Tseng, Jeng-Sen
Chang, Gee-Chen
Yang, Tsung-Ying
author_sort Lee, Po-Hsin
collection PubMed
description (1) Background: We aimed to evaluate the risk of hepatitis B virus (HBV) reactivation in lung cancer patients treated with tyrosine kinase inhibitor (TKI), particularly in those with resolved HBV infection. (2) Methods: In this retrospective hospital-based cohort study, we screened all lung cancer patients with positive hepatitis B core antibodies (anti-HBc) receiving systemic antineoplastic treatment during the period from January 2011 to December 2020. Cumulative incidences of HBV reactivation, and their hazard ratios (HRs), were evaluated after adjusting patient mortality as a competing risk. (3) Results: Among 1960 anti-HBc-positive patients receiving systemic therapy, 366 were HBsAg-positive and 1594 were HBsAg-negative. In HBsAg-positive patients without prophylactic NUC, 3-year cumulative incidences of HBV reactivation were similar between patients receiving chemotherapy and patients receiving TKI (15.0%, 95% confidence interval (CI): 0–31.2% vs. 21.2%, 95% CI: 10.8–31.7%; p = 0.680). Likewise, 3-year cumulative incidences of HBV-related hepatitis were similar between the two groups (chemotherapy vs. TKI: 15.0%, 95% CI: 0–31.2% vs. 9.3%, 95% CI: 2.8–15.7%; p = 0.441). In 521 HBsAg-negative TKI users, the 3-year cumulative incidence of HBV reactivation was only 0.6% (95% CI: 0.0–1.9%). From multivariable regression analysis, we found that the only independent risk factor for HBV reactivation in TKI users was HBsAg positivity (HR 53.8, 95% CI: 7.0–412.9; p < 0.001). (4) Conclusion: Due to high risks of HBV reactivation in HBsAg-positive TKI users, NUC prophylaxis can be considered. However, in patients with resolved HBV infection, such risks are lower, and therefore regular monitoring is recommended.
format Online
Article
Text
id pubmed-9820864
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98208642023-01-07 Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Treatment Lee, Po-Hsin Huang, Yen-Hsiang Hsu, Yu-Wei Chen, Kun-Chieh Hsu, Kuo-Hsuan Lin, Ho Lee, Teng-Yu Tseng, Jeng-Sen Chang, Gee-Chen Yang, Tsung-Ying J Clin Med Article (1) Background: We aimed to evaluate the risk of hepatitis B virus (HBV) reactivation in lung cancer patients treated with tyrosine kinase inhibitor (TKI), particularly in those with resolved HBV infection. (2) Methods: In this retrospective hospital-based cohort study, we screened all lung cancer patients with positive hepatitis B core antibodies (anti-HBc) receiving systemic antineoplastic treatment during the period from January 2011 to December 2020. Cumulative incidences of HBV reactivation, and their hazard ratios (HRs), were evaluated after adjusting patient mortality as a competing risk. (3) Results: Among 1960 anti-HBc-positive patients receiving systemic therapy, 366 were HBsAg-positive and 1594 were HBsAg-negative. In HBsAg-positive patients without prophylactic NUC, 3-year cumulative incidences of HBV reactivation were similar between patients receiving chemotherapy and patients receiving TKI (15.0%, 95% confidence interval (CI): 0–31.2% vs. 21.2%, 95% CI: 10.8–31.7%; p = 0.680). Likewise, 3-year cumulative incidences of HBV-related hepatitis were similar between the two groups (chemotherapy vs. TKI: 15.0%, 95% CI: 0–31.2% vs. 9.3%, 95% CI: 2.8–15.7%; p = 0.441). In 521 HBsAg-negative TKI users, the 3-year cumulative incidence of HBV reactivation was only 0.6% (95% CI: 0.0–1.9%). From multivariable regression analysis, we found that the only independent risk factor for HBV reactivation in TKI users was HBsAg positivity (HR 53.8, 95% CI: 7.0–412.9; p < 0.001). (4) Conclusion: Due to high risks of HBV reactivation in HBsAg-positive TKI users, NUC prophylaxis can be considered. However, in patients with resolved HBV infection, such risks are lower, and therefore regular monitoring is recommended. MDPI 2022-12-28 /pmc/articles/PMC9820864/ /pubmed/36615034 http://dx.doi.org/10.3390/jcm12010231 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lee, Po-Hsin
Huang, Yen-Hsiang
Hsu, Yu-Wei
Chen, Kun-Chieh
Hsu, Kuo-Hsuan
Lin, Ho
Lee, Teng-Yu
Tseng, Jeng-Sen
Chang, Gee-Chen
Yang, Tsung-Ying
Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Treatment
title Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Treatment
title_full Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Treatment
title_fullStr Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Treatment
title_full_unstemmed Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Treatment
title_short Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Treatment
title_sort reactivation of hepatitis b virus in lung cancer patients receiving tyrosine kinase inhibitor treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820864/
https://www.ncbi.nlm.nih.gov/pubmed/36615034
http://dx.doi.org/10.3390/jcm12010231
work_keys_str_mv AT leepohsin reactivationofhepatitisbvirusinlungcancerpatientsreceivingtyrosinekinaseinhibitortreatment
AT huangyenhsiang reactivationofhepatitisbvirusinlungcancerpatientsreceivingtyrosinekinaseinhibitortreatment
AT hsuyuwei reactivationofhepatitisbvirusinlungcancerpatientsreceivingtyrosinekinaseinhibitortreatment
AT chenkunchieh reactivationofhepatitisbvirusinlungcancerpatientsreceivingtyrosinekinaseinhibitortreatment
AT hsukuohsuan reactivationofhepatitisbvirusinlungcancerpatientsreceivingtyrosinekinaseinhibitortreatment
AT linho reactivationofhepatitisbvirusinlungcancerpatientsreceivingtyrosinekinaseinhibitortreatment
AT leetengyu reactivationofhepatitisbvirusinlungcancerpatientsreceivingtyrosinekinaseinhibitortreatment
AT tsengjengsen reactivationofhepatitisbvirusinlungcancerpatientsreceivingtyrosinekinaseinhibitortreatment
AT changgeechen reactivationofhepatitisbvirusinlungcancerpatientsreceivingtyrosinekinaseinhibitortreatment
AT yangtsungying reactivationofhepatitisbvirusinlungcancerpatientsreceivingtyrosinekinaseinhibitortreatment